At a glance
- Originator Aventis
- Class Antipsychotics
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 26 Jun 2002 No development reported - Preclinical for Schizophrenia in USA (unspecified route)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 08 Dec 1997 Preclinical development for Schizophrenia in USA (Unknown route)